\r\n\t[2] J. V. Moloney, A. C. Newell. Nonlinear Optics. Westview Press, Oxford, 2004.
\r\n\t[3] M. Kauranen, A. V. Zayats. Nonlinear Plasmonics. Nature Photonics, vol. 6, 2012, pp. 737-748.
\r\n\t[4] P. Dombi, Z. Pápa, J. Vogelsang et al. Strong-field nano-optics. Reviews of Modern Physics, vol. 92, 2020, pp. 025003-1 – 025003-66.
\r\n\t[5] N. C. Panoiu, W. E. I. Sha, D.Y. Lei, G.-C. Li. Nonlinear optics in plasmonic nanostructures. Journal of Optics, 20, 2018, pp. 1-36.
\r\n\t[6] A. Krasnok, A. Alu. Active nanophotonics. Proceedings of IEEE, vol. 108, 2020, pp. 628-654.
\r\n\t[7] M. Lapine, I.V. Shadrivov, Yu. S. Kivshar. Colloquium: Nonlinear metamaterials. Reviews of Modern Physics, vol. 86, 2014, pp. 1093-1123.
\r\n\t[8] Iam Choon Khoo. Nonlinear optics, active plasmonics and metamaterials with liquid crystals. Progress in Quantum Electronics, vol. 38, 2014, pp. 77- 117.
\r\n\t
The main objective of three-dimensional (3D) printing is to print a living cell or to create a three-dimensional biomaterial’s scaffold. This innovative technology allows the reproducible and also the automated fabrication of three-dimensional useful living tissues by depositing biomaterials layer by layer with an accurate positioning of cells. This method allows to make a three-dimensional object and an accurate as well as scalable geometries that are not suggested by any approaches like two-dimensional cell cultures [1].
The choice of applying these 3D functional living tissues comes from fundamental research [2]. Learning about the cell-biomaterial interface at the nanoscale stage is vital in accommodating flaws in tissues, nanoparticle-cell connections and organ defects [3], toxicological analysis or drug investigation [4], and transplantation in living objects [5]. Because of the rising complexity required for these tissues, 3D bioprinting is facing a lot of challenges in all of manufacturing areas. For example, the cell-encapsulated materials are commonly observable to chemical cross linkers for extended periods of time during storage prior to printing, which can harm the cells. At the time of deposition, the mechanical stress generated by the printing itself can result in damage and injury to cell functioning by cell shearing or extrusion [6]. The instant new printing tissue is fabricated, because of the small vascularity of printed material; limited nutrients are supplied in 3D construct [7]. Usually, the requirements for a suitable cell-containing dispensable biomaterial or bioink are generally biocompatibility, exhaustive, biomimicry, printability, and essential mechanical properties. This is the main cause for the huge number of the manufacturers of commercially accessible 3D bioprinters—particularly extrusion-based 3D bioprinter, where hydrogel bioinks are recommended [8]. Particularly, hydrogels are unquestionably the most comprehensive biomaterials applied as cell matrix in bioinks because they can be engaged as cell matrix and be modified to replace or mimic local tissue [9]. The physical and chemical characteristics of the hydrogels will verify the performance of the cells. Normally hydrogels are like as jelly-type materials, where the liquid component is water. Actually, hydrogels are just like water by weight, but practically any flow will not occur in the steady state because of the three-dimensional cross-linked polymer network inside the fluid, which provides them unique properties comparable to those of living tissues. Due to their different biocompatibility and printability, various hydrogels that support cell growth are associated with bioink fabrication, i.e., gelatin, agarose, polyethylene glycol (PEG)-diacrylate, and alginate that are commonly used as bioinks. While alginate is an anionic polysaccharide derived from brown seaweed and generally consists of two polymer blocks, (1-4)-linked β-
Cross-linking process of alginate.
Ionic cross-linking is a method where cells cause minimum damage. The cross-linking process happens moderately rapidly. Alginate has structural similarity to natural extracellular matrices that is why it has been applied widely in various biomedical applications as well as in the delivery of bioactive agents and wound healing. For cell encapsulation, alginate hydrogels are generally applied. The whole procedure is prepared by mixing cells in alginate solution, and after the mixing process, the alginate-cell mixture drops into a bath of calcium chloride solution. But in low concentrations (1–2%), due to low viscosity, the alginate solution is not printable. For increasing the viscosity, other materials like methylcellulose or gelatin can be mixed with alginate for preparing the printability. The structural correspondence of alginate to extracellular matrices creates a perfect biomaterial. Matrix stiffness is a functional determinant of stem cell differentiation, and alginate makes a potential material to manage stem cell growth. Alginate helps support the cell growth and also has a high versatility, extending to both in vivo and in vitro differentiation. For 3D bioprinting applications, for example, extrusion printing needs quick gelation. In this case alginate proposes high gelation procedures when combined with a multivalent cation, permitting gels to build up and deposit at constant temperature. It is also applied to encapsulate cells. This allows it to be an effective tool in varying the release rate of drug and growth factor delivery. While alginate degradation rate can be somewhat controlled by altering the MW of the alginate, it is still slow and difficult to control. The stiffness and composition properties of alginate bioink can be tuned to direct the differentiation of stem cells. Sodium alginate is available naturally which is biodegradable, non-immunogenic linear, and nontoxic polysaccharide polymer; it consists of mannuronic and guluronic acids [10]. The cost is also low being a marine material which can be extracted from the brown algae cell walls, forming hydrogel in certain conditions. Because of these advantages, bioengineers and material scientists use alginate for the preparation of bioinks in tissue engineering and regenerative medicines. The tissue fabrication by 3D bioprinting [11] and sodium alginate applications and properties [12] is currently separately reviewed. In this study we discussed the applications of alginate (Figure 2) in 3D bioprinting and blending alginate with other polymers to improve the biomaterial interaction of the cells attached to it [13].
Extrusion-based 3D bioprinting process.
The requirement for alginate-based biomaterials in drug delivery and tissue engineering is huge. As stem cells play a progressively more major function in the area of regenerative medicine [14, 15], the arrangement and relation between alginate-based materials and stem cells have been exclusively emphasized. Investigated by in vitro implantation and in vitro cytotoxicity assay, alginate-based scaffolds and microcapsules have shown minimum or minor cytotoxicity [16, 17]. These in vitro results recommended tunable connections between the bio-composites and the multiple platelet releasate-derived bioagents for improving hematoma-like fracture repair. Also, a simple invasive performance for in situ remedial of the implant structures through injection was established in rat tail vertebrae applying microcomputed tomography. These results confirmed that alginate-based scaffolds were capable of degrading, permitted the vascularization, and obtained minimum inflammatory responses after transplantation. Consequently, alginate-based scaffolds can present suitable characteristics as probable cell and drug carriers for tissue regeneration. The next sections explain the clinical and preclinical analysis of alginate-based biomaterials and applications.
Sodium alginate which is also known as sodium alginate or algin is a naturally extracted less costly polymer from the brown algae cell walls which have intracellular spaces [10]. Alginate is composed of (1-4)-linked β-
Varying biodegradability of solution of sodium alginate along with human adipose stem cells was printed with accurate definition. These kinds of bioinks have the capacity to modulate proliferation and stem cell spreading and withstand uniform cell suspension but are imperfect in the case of stem cell diffusion. Wu et al. [25] showed the procedure of slow degradation of the alginate by tissue incubation in a sodium citrate medium. The sodium citrate amount helped the optimization of the alginate degradation time. Chung et al. [18] improved the printing resolution and printability of pre-crosslinked printed constructs by adding alginate with gelatin, keeping the mechanical property and the growth of cells, and keeping pore diameter constant. In Figure 3 the procedure of alginate cross-linking with the added cells is shown.
Alginate with cell cross-linking process.
Alginate has been used for dressing of the wounds due to its of good conformability, absorptivity, and mild antiseptic properties coupled with biodegradability and nontoxicity and optimal water vapor transmission rate. Alginate-based products like electrospun mat hydrogels and sponges in dressing of wounds are very good substrates for healing of wounds, which include gel-foaming capability as soon as the absorption of the wound exudates and hemostatic capabilities [26]. It is already been mentioned that dressing wounds with alginate improves healing of wounds through monocyte stimulation to harvest higher cytokine levels like tumor necrosis factor-α and interleukin-6 [27]. Near the wound locations, cytokine production creates pro-inflammatory factors that are helpful for wound healing. Because of the existence of endotoxin in the alginate, a huge level of bioactivity is present in these dressings. In situ-forming wound dressing hydrogel can be produced by oxidized alginate and gelatin in low borax concentration as shown by Balakrishnan and Jayakrishnan [28]. The homeostatic gelatin effect is present in the mixed matrix and wound healing property of alginate, and the antiseptic borax property makes alginate the appropriate wound dressing material. Tissue-engineered cartilage requirement is immense and has a huge clinical importance. The main causes of disability of the articular cartilage are degenerative and traumatic lesions [29]. Nearly 100 million Chinese people suffer from osteoarthritis. Because of this reason, regeneration and repair of the cartilage have huge impact. The pros of the cartilage repair injectable therapies are that implant within the defect is not only maintained, but it also allows quick bearing of weight because of strength and stiffness which is attained quickly [30, 31]. For bringing close the mechanical properties of the native tissues with the scaffolds, the alginate physical properties are matched with the articular cartilage. Ge and solid alginate injectable hydrogel microspheres are used for cartilage regeneration. Many researchers have studied the growth factor in tissue engineering by using alginate hydrogels and alginate-based microsphere combinations [32, 33]. In one study the demonstration of immobilization of the positive effect of RGD to an alginate porous scaffold for endorsing TGF-β-induced human MSC differentiation is shown [34]. Bian et al. studied the co-encapsulation of the TGF-β including the microsphere of the alginate with the human MSCs in the hyaluronic acid (HA) hydrogels with respect to the design of the constructs implantable for the cartilage repair [35]. The immobilized RGD peptide facilitated the cell-matrix interaction which is proven to be an important feature for the microenvironment of the cells, allowing good cell availability for the chondrogenic-inducing molecule TGF-β. TGF-β-laden alginate microspheres in combination with alginate hydrogels forms a compound carrier which may retain TGF-β bioactivity in the construct and encourages hondrogenesis of MSCs when inserted. The animal experiment displayed that chondrocytes planted into the microsphere scaffold lived habitually in SCID mice and cartilage-like constructions were created after 4 weeks of imbedding.
In the past years, drug delivery carriers draw huge interest because of large biomacromolecules like genes and proteins as well as low-molecule weight drugs which can be delivered in a targeted or a localized manner [36, 37]. Because of its biodegradable and biocompatible nature, alginate is used as a carrier for encapsulating and immobilizing drugs, cells, proteins, and bioactive molecules [38, 39]. Currently, alginate-based carriers like colloidal particles, polyelectrolyte, and hydrogels are under examination; few of them are practically used. Many researchers have examined the alginate-based hydrogel blends, microspheres, and porous scaffolds for precise drug delivery in various tissue engineering fields [40, 41]. Hollow microsphere of alginate-based hollow microsphere has huge applications as drug delivery carrier, micro-reactor, and biosensor [42]. The construction of the hollow microcapsules can be created by successive self-assembly of positively and negatively charged polyelectrolytes by layer-by-layer (LbL) technique. The alginate microcapsule is studied well with respect to precise releasing and loading parameters. The attempt to fabricate microcapsule biopolymer has been made by dropping alginate/chitosan in a decomposable colloid particle after removal of its core is done in an appropriate pathway. For the production of hollow microcapsule, chitosan and alginate are interchangeably deposited in CaCO3 with electrostatic biocompatibility [43]. The chitosan/alginate microcapsule functionalities and properties can be preciously adjusted by changing the microcapsule composition, exterior stimuli introduction, and thickness. Immersing alginate microcapsule in various pH solutions helps in the degradation of the microcapsules which also determines the material role and encapsulation layers for keeping microcapsule stability in various pH conditions. The addition of PEG to the microcapsule allows protection against acidic conditions, whereas the coating layer number only affects the swelling properties, not the microcapsule Young’s modulus which was revealed by Wong’s study [9]. For surface micro-patternings and microarray systems, 3D platform alginate hydrogels are used. For in situ gelation, a few aliquots of solution of gelatin were trapped selectively on hydrophilic area by a process called dipping process. Cells with various adhesion properties were captured by gel pattern alginate on the hydrogel structures.
Various CYP450 enzymes like vascular endothelial growth factor (VEGF) and β1-integrin upregulation showed that the stage gave many in vitro conditions that result in allowing cells in their natural phenotypes.
For the reconstructive surgery, bone regeneration is an important challenge. It occurs due to tumor removal and trauma. To repair the bone, a good initiative is to induce osteogenesis in situ. To complete this process, one method is by using stem cell differentiation to form bone tissue and then seeding them in an injectable scaffold [44, 45]. As of now there are numerous investigations and studies on alginate-based injectable scaffolds for the bone regeneration. By using MSCs and alginate scaffolds, satisfactory bone tissue formation was noticed [46, 47]. For this reason the application of alginate for gel tissue generation is commonly used which displays angiogenic and osteogenic properties. Many researchers showed bone regeneration by means of injectable constructs by joining microspheres or alginate-based hydrogels that were combined with interchangeable ASCs or MSCs [48]. These studies demonstrated the potential of bone morphogenetic protein (BMP) and TGF-β delivery to induce osteogenic differentiation to mature osteocytes from MSCs and ASCs. Kolambkar et al. presented a growth factor hybrid system of delivery that comprises of a nanofiber mesh tube which is electrospun for directing regeneration of bone along with alginate hydrogel peptide modified in the tube for fixed recombination BMP-2 (rhBMP-2) release [49]. The discharge of fixed transport of rhBMP-2 through alginate hydrogel was important for significant regeneration to take place. The mixed technology can be used clinically for the regeneration of bone in cases as huge bone defect and nonunion fractures.
The naturally available biopolymer alginate is cheaper which forms hydrogel by cross-linking with various salts like BaCl2, CaCl2, and ZnCl2 which showed good biocompatibility and printability.
This is broadly applied for cartilage, bone, and vascular tissue printing. Few drawbacks of alginate are slow degradation and poor cell adhesion; in many research, it is shown that alginate has poor cell differentiation and cell proliferation, and for this reason, it is used as a blend with other polymers. To improve these limitations, blending alginate with other polymers like honey, gelatin, and Arg-Gly-Asp adhesions is done. Furthermore, for faster normal degradation in regenerative medicine, oxidized alginate and/or sodium citrate is found to be useful. The combination of 3D printing alginate for cartilage and electrospinning is used positively in various tissue engineering fields. Furthermore, mixing alginate with biopolymers like polycaprolactone and nanocellulose has shown positive results. In bioprinting using coaxial or triaxial nozzles is found out to be promising and provided brilliant results. To improve the mechanical properties of the alginate-based structures used in bone tissue engineering, mixing alginate with other polymers like bio-silica, polyphosphate, polycaprolactone hydroxyapatite, and gelatin is found to produce an excellent result. We think this review will allow researchers to investigate more advanced and improved bioink for 3D printing and also help to invent suitable and more appropriate bioink for various tissue engineering applications
Digital Health (DH) is an evolving multidisciplinary scientific field that seeks to monitor medical problems while also preventing new ones with the ultimate aim of improving the overall quality of health. [1, 2] These means of information technology can be applied through mobile health (mHealth), telehealth/telemedicine, activity trackers, personal wearables, and remote monitoring, and represent an interplay of the art and science of medicine to achieve overall improvement in health. [2] Due to its broad nature, DH is usually used interchangeably with health information technology (HIT).
Electronic-health or E-Health is characterized by an intersection of public health, medical informatics, the business of healthcare, information science, and health services to achieve better health for users. [3] The term comprises both technical aspects like hardware, software, and internet broadband and social elements centered on the way of thinking and networked global effect through information technology. [3]
Big data refers to an enormous data set existing as either structured (organized), unstructured (unorganized), or mixed. [4, 5] These characteristics have been described as the paradigm of 4 “Vs:” volume, velocity, variety, and veracity. [4, 6, 7, 8] Generally, about 2.5 quintillion bytes of data are created every day worldwide and it is rather amazing that 90% of it was created in the past 5 years. [9]
Sources of big data span a wide spectrum including posts from social media sites to sensors and navigation devices. It is a big challenge to determine the amount of data generated yearly by the healthcare industry due to the complex nature of healthcare data with heterogeneous sources and structures. [10] Healthcare data sources include electronic health record data (EHR), prescription compliance and refill rate, personal activity tracking devices, laboratory data, cell phone-based geographical monitoring, and remote telemedicine monitoring. About 500 petabytes of data were generated by electronic medical records alone in 2012 and it is expected to reach 25,000 petabytes by the end of 2020. [11] The various methods/processes of big data analysis are referred to as analytics.
Many factors are responsible for our contemporary adoption and application of big data and DH. The greatest driving force is the dynamic state of computer power relative to it cost of acquisition rightly predicted by Moore’s law. It states that computer power (in terms of speed and memory storage) will double every two years at the same price. In 1956, you would have had to pay $10 million for one gigabyte of storage. In 1981, the cost of a gigabyte was $ 300,000 and by the year 2000, it had dropped to $10. In 2010, the price of storing a gigabyte of data dropped to just 10¢. [12]
Another technology-based driver is the advent of cloud computing. This is the process of utilizing remote computer networks via the internet to manage, process, store, and manipulate data rather than utilizing the local or personal computer connected to the network. This phenomenon allowed for an exponential increase in the capacity of local computers, hence serving as a driver for the “internet of things,” or the interconnectivity between various devices embedded with electronics, software, and sensors. Its ability to impact all major players in the healthcare industry, including the patient, healthcare provider, healthcare regulators, payers, and vendors, has been described as the Internet of Medical Things (IoMT). [13]
Another driver of big data application and DH is the advancement in genomic medicine and gene therapy. [13] Gene mapping and sequencing is an integral part of big data as it utilizes various bioinformatics processes for interpretation and storage.
The most important factor remains the paradigm shift in the role of the patient as a “consumer” of health services. Patients seek to better manage their health by playing active roles through information gathering on the internet and especially via social media networks. [14] One in three Americans has gone online to investigate a medical condition. [15] Another important factor is the changing demographics of the aging population and prevalence of chronic diseases leading to escalating cost of healthcare. In fact, the cost of chronic diseases accounts for up to 75% of healthcare cost in the US. [16]
DH innovations have shown some promising results as a means of achieving efficient and cost effective care without compromising quality of care. [17] The mandate from regulators to shift from a volume- to value-based reimbursement model is a testament to the fact that the shift to reward quality, efficiency, and collaborative care is here to stay. [18] The incentive for hospitals to adopt meaningful use of digital technology due to the Health Information Technology for Economic and Clinical Health (HITECH) act, enacted as part of the American Recovery and Reinvestment Act of 2009 [19], resulted in widespread adoption of electronic health records system in the US.
Data is the foundation of DH. Data science is the term used to describe the scientific study of the creation, validation, and transformation of data to create meaning. [20] It is composed of multiple disciplines like statistics, mathematics, and computer science (Figure 1). Data science is an overarching field that underlies many DH innovations like artificial intelligence (AI), machine learning (ML), deep learning, reinforcement learning, and data mining (Figure 2). [21]
Data science as a multidisciplinary field of study. Diagram reprinted with permission from Robert (Bob) Hoyt, MD, FACP, FAMIA, ABPM-CI.
Relationship between data science, artificial intelligence, and machine learning. Diagram reprinted with permission from Robert (Bob) Hoyt, MD, FACP, FAMIA, ABPM-CI.
ML is a sub-discipline of AI that uses algorithms to identify patterns in data, as such giving computers the ability to learn without being explicitly programmed to create predictive models based on training data and validated on test data.
Data mining refers to the discovery of patterns in large data sets with methods at the intersection of unsupervised learning, traditional statistics, and database systems. [22] Predictive analytics involves learning from historic data to predict likely future outcomes with an expressed degree of certainty. Clinical decision support (CDS) programs are systems set up to augment clinicians in their day-to-day complex decision-making processes. [23]
All the factors driving DH and HIT are geared towards a paradigm shift from our present state of “sick care” to “high value healthcare.” [24] Healthcare value definition is rather challenging because of its complex ecosystem with many different stakeholders and their associated conflicting goals and expectations. [25]
Nevertheless, the meaning which most stakeholders can relate to is the concept of value in healthcare as outcome (rate of quality outcome) per cost needed to achieve a result. [26] It is represented mathematically as quality/cost and is the extent to which our health interventions achieve desired health outcomes that are consistent with evidence-based knowledge. [27] Essentially, it is healthcare which is cost effective and efficient, safe, patient-centered, and equitable, with the aim of achieving the best outcome in terms of morbidity and mortality. [28, 29]
Patient safety on the other hand is the foundation of quality care. The Institute of Medicine (IOM) believes that health quality is indistinguishable from Patient safety. [30, 31] I will define patient safety as a system of care delivery that prevents errors built on a culture that learns from previous mistakes. In simple terms, it is a system that functions to avoid harm to patients. [32] And healthcare quality will be analyzed in the context of the quadruple aim of quality improvement. [33]
The quadruple aim is a compass to optimizing health system performance which is made up of four components: improving health outcome and experience of care, improving population health, improving healthcare cost, and improving staff engagement.
To overcome the inefficiencies of the healthcare sector in the US, healthcare organizations are encouraged to adopt methodologies like the lean or six sigma methodology that has a track record of optimizing systems in other sectors. Lean methodology involves processes put in place to reduce waste in every procedure, process, and task based on an ongoing system of improvement and learning, and focuses on eliminating waste by avoiding efforts that do not add value to the patient. [34] Six sigma, on the other hand, is a metric-driven system used to reduce medical errors, defects, and variations in output by applying the following: design, measure, analyze, improve, and control (DMAIC). [35]
Examples of successful applications include reducing time to life saving procedure like door-to-balloon time in cardiac catherization, unnecessary antibiotics prescriptions, turnaround time for pathology reports, and clinic wait times, and streamlining electronic payment for vendors. [35, 36] Optimized symptoms that run efficiently can maximize the output of DH technologies. [37]
The US spends up to 17.6% of its GDP on healthcare which is far more than that of all the other developed nations combined at 9%. Despite this amount of spending, the US ranks poorly in the World Health Organization’s ranking of health system performance. [38] The public health improvement goals of the quadruple aim correspond with the goal of contemporary medicine which involves the need to achieve cost-efficient quality health through participatory and personalized medicine, ultimately ensuring optimum predictive and preventive medicine. [37]
The last component of the quadruple aim is provider satisfaction and engagement. Healthcare quality can hardly be achieved without an engaged healthcare workforce. Burnout involves a state of emotional exhaustion (with or without physical fatigue) and powerlessness to change the status quo. [39, 40, 41] Up to 60% of healthcare providers experience one or more symptoms of burnout in the US [42, 43] and suicide rate amongst physicians in the US is higher than those of the general population. [39] Multiple factors are responsible for burnout which include high data and information volumes and changes in the healthcare model including a shift from volume- to value-based care. [40]
Even cutting-edge EHR functionalities involving AI/ML for predictive clinical decision support are potential sources for provider dissatisfaction and burnout due to lack of regulation mandated user-centered design approach in their product development. [44, 45]
The 4th Industrial Revolution is philosophical and ideological construct by the world economic forum which postulates on how digital, physical, and biological technology have uniquely combined together in our contemporary world creating new opportunities and challenges. [41]
The first Industrial Revolution was powered by steam in the 18th century, the 2nd powered by electricity in the 19th century, and the 3rd in the 20th century powered by technology. [46] Although the 4th Industrial Revolution is considered by many as a direct extension of the 3rd, the 4th differs due to the unprecedented volume and velocity of data in addition to enhanced global interconnectivity. [47]
To reap the potential benefits in the 4th Industrial Revolution, it is imperative for the healthcare sector to adopt practices like the agile methodology with the ability to “fail fast” while learning quickly in an iterative manner to achieve the desired state of healthcare quality. [48]
The peer reviewed articles reviewed for this chapter were obtained from a broad literature search performed in PubMed, and Google scholar. Search terms included; “4th industrial revolution”, “digital health” “quality improvement”, “Digital health and patient safety”, “applications of digital health for healthcare quality”, “Digital health security”, “Regulation of digital health”. Due to the relative novelty of digital health and the 4th industrial revolution, other sources of relevant information like digital health magazines, quality improvement magazines and health informatics websites were also refer referenced.
The full potential of DH remains unquantifiable at this juncture mainly because of a shortage of well-conducted evaluation studies showing evidence of value added by new tools, especially those involving AI/ML. [49, 50] The rapid acceleration of DH methods and overall geometric advancement is such that any novel technology is almost outdated upon arrival. Despite all these setbacks in the application of DH, there have been some notable applications which have shown some promising results.
Remote patient monitoring involves patient data collection by appropriate providers with data either patient reported or automatically collected via apps, sensors, and any other specific gadget (glucose meters, blood pressure cuffs, or scales). This produces a vast amount of real-time data which is usually beyond the analytic capacity of the healthcare provider, creating an excellent scenario for predictive analysis of the data using ML and similar tools. [51, 52]
ML analysis of bidirectional remote monitoring and EHR data has potential to provide great insights on the overall quality of individual patient care. [51] Remote monitoring has successfully been applied to diseases like congestive heart failure management (resulting in a 30% reduction in admission) [44] and diabetes management (resulting in better glycemic control compared to standard of care). [53]
Utilizing standardized risk scores and predictive analysis, some organizations have been able to predict patients that are likely to be readmitted to the hospital within 30 days after discharge. [54] Apart from the mortality benefits to the patients, the institution is also able to benefit financially as they avoid significant penalties associated with readmissions imposed by Medicare under the Medicare’s Hospital Readmissions Reduction Program (HRRP). [55]
Algorithms that predict the likelihood of hospitalized patients to develop acute kidney injury during their index hospital stay have been successfully developed as well. [56] Additionally, significant reduction in sepsis mortality by algorithms leveraging the patient’s data in the EHR to predict severe sepsis have also been achieved. [57]
An algorithm developed using EHR data was able to predict suicide risk in individuals better than traditional clinical methods. [45] Predictive analytics tools continue to demonstrate their role in the overall reduction of in-hospital adverse events. [58]
The use of CDS in antibiotics choice has been shown to significantly increase antibacterial susceptibility, thereby reducing the need for broad-spectrum antibacterial agents and the risk of antibiotic resistance. [59]
Considering the complexity of cancers, the vast amount of knowledge released daily, and expansion of treatment options, the incorporation of genomic data in treatment modality all make it very challenging for clinical oncologist to choose the best personalized therapy. [47] CDS in oncology have shown some potential with assisting clinicians to navigate the challenges inherent in treatment modalities and have performed similar to multidisciplinary tumor boards. [60]
The risk of failure in predictive analytics and CDS can result in significant patient harm, hence why mitigation of risk and human oversight is still an essential part of their deployment.
Predictive analytics have been used to accurately identify patients likely to skip appointments without advanced notice. [61] Additionally, they have been successfully used to anticipate peak and low utilization periods by mining previous utilization data. [62] This knowledge assists leadership in planning for changes in volume so they are ready with corresponding resources required to navigate changes in volume. Other proven applications of AI/ML include automation of invoice processing, correct coding for reimbursement, and processing of insurance denials and claims. [51]
The optimal state of public health of a nation should emphasize predictive and preventive care in addition to easy and equitable access to healthcare to improve overall mortality and morbidity. While the US health system falls short of these public health essentials in comparison to other developed nations, DH application has shown some promising outcomes. [57]
Individual risk for developing chronic disease can be ascertained with a high degree of certainty. Integrative genetic profile has been applied successfully to determine high risk of diabetes mellitus type 2 in an individual who did not have common risk factors like obesity and family history. [63]
Direct-to-consumer genetic testing for risk factors of diseases are also gaining traction with commercialized proteomic analysis testing kit for diseases like Alzheimer’s disease. [53] Utilizing proteomic analysis of specific blood proteins was able to a determine if a lung nodule was benign with 90 percent accuracy during screening. [64]
Similar DH based programs can assist with opioid epidemics as they have been proven to result in a 30% reduction in statewide opioid prescriptions. [65, 66, 67] Another promising application involves the development of opioid abuse risk profiles of patients using ML model and EHR data to predict patients who are prone to future abuse and overdosage. [68]
The healthcare provider shortage coupled with the increasing aging population are factors that exacerbate healthcare access and inequity across the nation. [54] This shortage of healthcare providers and lack of access to health is worse in rural areas where 65% of non-metropolitan counties lack psychiatrists and 45% are without psychotherapists. [55] Telemedicine has shown strong evidence as a means of increasing access to mental healthcare in rural areas by providing effective treatment for mental health conditions, improving medication adherence, and effective follow up and continuity of care. [69] AI-powered chat bots can be used for initial triage based on symptoms and an expert engine can determine type and nature of visit necessary (either a virtual check-in or a face-to-face visit).
The US Government’s 21st Century Cure Act prioritized improvement in HIT, including interoperability, patient access to their health records, and improved regulatory oversight for DH. [56] As part of the Cures Act, the Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) has adopted analytics methodologies like “in silico” testing. This is particularly important in diseases where the smaller patient sample sizes is often a limitation of their clinical trials. [70]
Despite the excitement which comes from the potential of DH for quality improvement, challenges exist. Not considering these challenges is akin to chasing “shiny objects” with potential for negative and adverse consequences both in the short and long term.
Interoperability is the ability of different information systems to access, exchange, and cooperatively use data in a coordinated manner, within and across organizational and regional boundaries, to provide timely and seamless portability of information for optimal healthcare. [57] The healthcare data ecosystem in the US is highly fragmented with different EHR systems as a repository of patient data. These disparate EHR systems are not connected and as such their lack of interoperability is a huge set back and operational burden to DH implementation for patient safety.
The lack of consensus evaluation standards in DH is also a barrier to determining the value added. [71] The world of biomedical sciences is accustomed to the traditional randomized control trials as a gold standard for evaluation. Unfortunately, this is not always a practical option for most DH applications due to variation in input data and a lack of stability of deliverables needed to quantify outcomes in RCT. [72] Although various evaluation framework exists across the industry, no consensus standards have been generally accepted across board. [73] Thus, we have no standardized method of determining the effectiveness of the over 300,000 medical apps available. [71]
Most stakeholders consider DH a singular fix for the inefficiencies in healthcare. [74] But, for any DH innovation to be successful, design and implementation need to be compatible with all elements of the system engineering initiative for patient safety (SEIPS) model. [75] The elements to consider in this model include consideration of persons involved and their peculiarities, available technology and tools for success, organizational culture, type of tasks, environmental layout, care and information process/flow, and patient outcomes.
This lack of overall socio-technical consideration manifests as the absence of stakeholder input in the development of new DH tools, consequently leading to poor usability of the DH tool like the EHR, which is a significant contributor to provider burnout and inefficiency. [76] Additionally, the low usability of EHR increases the cognitive load of the healthcare provider, which contributes significantly to medical error. [77]
Lack of overall consideration in the context of the socio-technical landscape increases the chances of unexpected consequences like creating workarounds in the EHR with a negative impact on patient safety. [78]
Government and regulatory agencies struggle to provide a clear-cut regulatory pathway for DH tools. Restrictions and barriers to telemedicine adoption like provider portability of license to practice across state lines, geographical restrictions, and specifics about reimbursement parity still exist and have only been temporarily lifted during the 2019–2020 COVID-19 pandemic. [79] The lack of consistent regulations of proliferating medical apps prevents a high risk to patient safety. [80]
Innovations in most healthcare organizations in the US are driven by the need to meet basic regulatory compliance metrics and financial viability (bottom line). Healthcare leadership are more concerned about the bottom line while regulators are mostly concerned about patient safety. Patients are concerned about convenience of service and safety.
Another important issue with DH and big data is the constant threat to healthcare data integrity and security. These occur in the form of hacking, malware, unauthorized access, and data theft. In 2019, almost 41 million medical records were affected by healthcare data breaches, mostly through hacking and ransomware attacks. [81] The average cost of these breaches to affected healthcare organizations was about $6.5million. [82]
Presently, resources (infrastructure, expertise, and personnel) required to utilize DH/big data are not available to all and confer a competitive advantage to those who possess them. The resulting disparity and its consequences are contrary to the outcome we seek from DH innovations. Nearly half of the world’s population do not have reliable internet access. This phenomenon is well known and described in the literature as the “digital divide.” [64].
Explainability describes the degree of transparency and traceability of the outcome of any AI/ML model. [83] This is particularly important because of the non-linear, highly nested structure of complex algorithms, which makes us unaware of how they arrive at their conclusion or output. [65] This characteristic, described as the “black box” phenomenon, represents a huge setback in the application of AI/ML in healthcare. [66] This is mainly due to the sensitive nature of health operations and its low tolerance for lack of transparency in decision making. Thus, those who develop AI tools must involve primary stakeholders and decision makers from the beginning to assist with transparency and adoption by end users.
Predictive analytics and model development rely heavily on not just high volume data but also high quality data. Unfortunately, most available healthcare data are unstructured and interspersed with artifacts/“noise” which increases the chances of spurious model output even in the setting of a near-perfect model. [84]
Adversarial attacks are either targeted or non-targeted inputs uniquely engineered to cause mis-classification and fool an AI model to produce an incorrect output. [67] This tendency for adversarial attacks in medical AI applications is due to the inherent monetary incentive for fraud in healthcare as an industry with more than three trillion-dollar annual expenditure. [68] A second reason is the technical vulnerability of the models in healthcare.
In an ethnically diverse nation like the US, an excellent AI/ML output can only be achieved if the training data utilized are equally diverse. If there is no conscious effort to ensure diversity of training data, the algorithm would be propagating the conscious and subconscious bias that exists in our society. [85] An example is an algorithm developed to detect malignant melanoma.
Malignant melanoma is treatable if detected earlier and ML algorithm can aid in early detection. However, the algorithm is at risk of bias and disparity already grounded in our society due to the lack of adequate representation of people of color/darker skin tone in training data. [85] This limitation can hinder the utility of the algorithm for people of color. Presently, most ML programs like the International Skin Imaging Collaboration Project source their training dataset mostly from fair skinned populations in the US, Australia, and Europe. [85]
Other manifestations of propagated bias include: fit bits® produces inaccurate heart rate in people of color [86] and biases and mislabeling of facial recognition software with algorithm output of people of Asian descent represented as blinking facial images. [69] The risk here is the tendency to worsen all our societal ills like health disparity, inequality, gender bias, and racism, which are all hindrances to quality public health for all.
ML algorithms are only as good as the quality of their training data set. Unexpected data points and sudden changes in pre-defined events will likely result in poor performance. This lack of initiative of the ML/AI algorithm is coupled with a lack of empathy displayed in a human-to human healthcare interaction, representing a setback for patient satisfaction.
There exists a lot of ethical dilemmas in the application of ML tools which cannot be ignored. One of the dilemmas we face is the need for disclosure whenever ML tools are used in direct patient care. [87] In most of these applications, patients are not aware that the care from their clinician is augmented by ML algorithms even when the effectiveness of these algorithms are yet to be proven. [70] There is still no consensus amongst providers and patients alike regarding the right ethical approach to tackle this issue.
Evaluation of DH tool/intervention is the objective and systemic assessment of a DH intervention/tool with the sole purpose of determining the efficacy, efficiency, impact, sustainability, and extent to which pre-set specific objectives are met. According to the World Health Organization, “evaluation asks whether the DH tool/project is doing the right things, while monitoring asks whether the DH tool/project is doing things right.” [88] Although monitoring and evaluation (M&E) are distinct entities, they are usually addressed simultaneously from pre-prototype/prototype stage through the pilot and demonstration/display of tool up to the stage of scale up.
The first stage of M&E is to identify the stage of maturity of the tool. This determination will play into the methodology/framework utilized for M&E.
After identifying the stage of maturity of tool, the next step would be to ascertain concrete baseline expectations of the tool and define appropriate claims based on stage of maturity of the DH tool. The usability of the tool is an important measure that should be evaluated in all the stages of maturity from early to late stages. It is also important to set expectations in relation to time to deliverables to guide M&E activities. A tool being developed to shorten wait time at the clinic should get input from patients about their pain points while setting M&E standards.
The next steps is to define the M&E framework to guide the process. There are well-established frameworks for M&E published in the literature; however, I favor structures that are result oriented. [73, 88] To strengthen the evaluation framework, it should be developed through a stakeholder consultative process and reviewed as needed during the life cycle of the project.
The next step is to determine who will be carrying out these M&E activities, how many resources will be required, and the time-based deliverables expected from the team in charge.
Considering the degree of rapid transformation and dynamism we are experiencing with the 4th Industrial Revolution, only organizations positioned to adapt will succeed. This adaptation requires that all stakeholders learn new skill sets as we navigate this transformation.
Government regulatory oversight teams are needed to craft rules/policies to regulate broad DH principles like security, privacy/disclosures of DH tools, fairness and equity of implementation, and avoidance of bias in implementation. The regulatory rigors placed before approval of DH tools should be based on the level of risk of a DH tool in the event of failure, determined by a baseline failure mode and effect analysis.
Government mandates should ensure that DH tools maintain a well laid out process for human oversight of implementation no matter how “perfect” the tool may be.
Professional organizations can assist with navigating complexities as it relates to specific requirements for M&E of DH tools developed for their subsections. Once general overall policies are established by the government or regulatory agencies to address fundamental societal issues to ensure quality and safety of DH, expert organizations can help narrow down these policies to suit their subsection of the healthcare ecosystem.
Payers are responsible for processing patient eligibility, enrollment, claims, and payment of healthcare services. In the US, payers exists as either governmental (Medicare/Medicaid) or private entities. A testament to the fragmented nature of the US healthcare system is the fact it has more than 900 healthcare payers as of 2020. [89] These entities have a significant influence on how healthcare is delivered in the US based on their reimbursement schemes. As part of their basis for reimbursement of any healthcare service which has been augmented by DH, they should mandate standardized M&E of the tools to justify compensation; it is equally important to be wary of mandates that would stifle innovation.
Healthcare vendors ranging from device and pharmaceutical manufacturers to core HIT and analytics developers and entrepreneurs are numerous; in fact, there are more than 370 HIT-specific vendors in the US as of 2020. [90] Vendors also have a role to play in ensuring that DH tools do not only offer novelty but also have an in-built yardstick for evaluating their comparative effectiveness for objective assessment of their overall impact upon implementation.
Considering that these centers are the avenue for implementation of most DH tools, they must insist on implementing DH tools with a track record of adding value to patient safety and improving healthcare quality. In the event the DH tool intended for use is novel with no track record, the organization should demand a concrete basis and claims for M&E. This will assist with an objective comparison of the impact of a new tool with the status quo.
Healthcare providers are often laggards and usually conservative in the adoption of new tools, as consequences of failure are very high with regards to patient safety. [91] Nevertheless, the 4th Industrial Revolution permeates all sectors of healthcare and healthcare providers are directly impacted. They must actively learn how to become an information specialist and ask the right questions about a potential DH tool to be implemented. [92] Considering that they will be utilizing these tools to make important decisions about patients and their safety, it is important they are well equipped with the knowledge of how to evaluate and monitor the DH tools for optimal healthcare quality.
Patients and caregivers are the ultimate intended beneficiaries of DH tools, as any failure of DH tool implemented will have an adverse consequence on their safety and quality of health. [93] In this new dispensation, they must prompt their healthcare providers to ask the right questions from the DH tools’ developers. Patients and caregivers should understand that, as we progress further into the 4th Industrial Revolution, these DH tools will increasingly play an essential role in decisions about their care directly or indirectly.
The quadruple aim describes healthcare value as improved health outcomes, increase patient satisfaction, reduced costs, and healthcare provider satisfaction/fulfillment. DH tools have shown potential in improving healthcare quality and achieving the quadruple aim, such as promoting behaviors like healthy eating and smoking cessation, improving outcome in people with chronic conditions like cardiovascular diseases, and increasing health access through telemedicine and remote monitoring. [72, 94]
Although there are demonstrated impact of DH tools in healthcare quality, it is still not an overall fix able to transition us from our state of sick care to optimum healthcare quality alone. Its applications and implementation are filled with many limitations presently hindering the achievement of its full potential in healthcare quality improvement. We cannot figure out how effective a tool is without a pre-defined basis on how to ascertain its effectiveness. Presently the evaluation and performance measurement in healthcare is costly, redundant, and labyrinthine. [78]
DH tools are only part of the solution and not an ultimate solution. As such every DH tool implementation should be considered in the context of the overall socio-technical ecosystem. All innovations should be based on stakeholders’ input right from the start of conception. No matter how effective a piece of technology is, if it is implemented in a poorly optimized system, it will likely result in failure.
Navigating the 4th Industrial Revolution requires that all stakeholders play an active role in this transition. No doubt it brings forth many possibilities for healthcare quality improvement; however, in the absence of evaluation standards and a systematic approach to its implementation, we risk being immersed in hype born out of the hope of an elusive better outcome. DH tools are key components in achieving value in healthcare, but it is not the destination and neither is it the goal, but rather a catalyst in the process of obtaining the ultimate goal of the quadruple aim.
The author declares no conflict of interest.
Abbreviation | Meaning |
---|---|
DH | Digital Health |
mHealth | Mobile Health |
HIT | Health Information Technology |
IoMT | Internet of Medical Things |
HITECH | Health Information Technology for Economic and Clinical Health |
ML | Machine learning |
AI | Artificial Intelligence |
DMAIC | Design, Measure, Analyze, Improve, and Control |
GDP | Gross Domestic Product |
HER | Electronic Health Record |
HRRP | Medicare’s Hospital Readmissions Reduction Program |
CDS | Clinical Decision Support |
FDA | Food and Drug Administration |
M&E | Monitoring and Evaluation |
IntechOpen is the first native scientific publisher of Open Access books, with more than 116,000 authors worldwide, ranging from globally-renowned Nobel Prize winners to up-and-coming researchers at the cutting edge of scientific discovery. Established in Europe with the new headquarters based in London, and with plans for international growth, IntechOpen is the leading publisher of Open Access scientific books. The values of our business are based on the same ones that any scientist applies to their research -- we have created a culture of respect, collegiality and collaboration within an atmosphere that’s relaxed, friendly and progressive.
",metaTitle:"Social Media Community Manager and Marketing Assistant",metaDescription:"We are looking to add further talent to our team in The Shard office in London with a full-time Marketing and Communications Specialist position. The candidate will bring with them a creative and enthusiastic mindset, high level problem-solving skills, the latest marketing and social media platforms skills and strong involvement in community-best practices to engage with researchers and scholars online. The ideal candidate will be a dynamic, forward thinking, approachable team player, able to communicate with all in the global, growing company, with an ability to understand and build a rapport within the research community.",metaKeywords:null,canonicalURL:null,contentRaw:'[{"type":"htmlEditorComponent","content":"We are looking to add further talent to our team in The Shard office in London with a full-time Social Media Community Manager and Marketing Assistant position. The candidate will bring with them a creative and enthusiastic mindset, high level problem-solving skills, the latest marketing and social media platforms skills and strong involvement in community-best practices to engage with researchers and scholars online. The ideal candidate wll be a dynamic, forward thinking, approachable team player, able to communicate with all in the global, growing company, with an ability to understand and build a rapport within the research community.
\\n\\nThe Social Media Community Manager and Marketing Assistant will report to the Senior Marketing Manager. They will work alongside the Marketing and Corporate Communications team, supporting the preparation of all marketing programs, assisting in the development of scientific marketing and communication deliverables, and creating content for social media outlets, as well as managing international social communities.
\\n\\nResponsibilities:
\\n\\nEssential Skills:
\\n\\nDesired Skills:
\\n\\nWhat makes IntechOpen a great place to work?
\\n\\nIntechOpen is a global, dynamic and fast-growing company offering excellent opportunities to develop. We are a young and vibrant company where great people do great work. We offer a creative, dedicated, committed, passionate, and above all, fun environment where you can work, travel, meet world-renowned researchers and grow your career and experience.
\\n\\nTo apply, please email a copy of your CV and covering letter to hogan@intechopen.com stating your salary expectations.
\\n\\nNote: This full-time position will have an immediate start. In your cover letter, please indicate when you might be available for a block of two hours. As part of the interview process, all candidates that make it to the second phase will participate in a writing exercise.
\\n\\n*IntechOpen is an Equal Opportunities Employer consistent with its obligations under the law and does not discriminate against any employee or applicant on the basis of disability, gender, age, colour, national origin, race, religion, sexual orientation, war veteran status, or any classification protected by state, or local law.
\\n"}]'},components:[{type:"htmlEditorComponent",content:'We are looking to add further talent to our team in The Shard office in London with a full-time Social Media Community Manager and Marketing Assistant position. The candidate will bring with them a creative and enthusiastic mindset, high level problem-solving skills, the latest marketing and social media platforms skills and strong involvement in community-best practices to engage with researchers and scholars online. The ideal candidate wll be a dynamic, forward thinking, approachable team player, able to communicate with all in the global, growing company, with an ability to understand and build a rapport within the research community.
\n\nThe Social Media Community Manager and Marketing Assistant will report to the Senior Marketing Manager. They will work alongside the Marketing and Corporate Communications team, supporting the preparation of all marketing programs, assisting in the development of scientific marketing and communication deliverables, and creating content for social media outlets, as well as managing international social communities.
\n\nResponsibilities:
\n\nEssential Skills:
\n\nDesired Skills:
\n\nWhat makes IntechOpen a great place to work?
\n\nIntechOpen is a global, dynamic and fast-growing company offering excellent opportunities to develop. We are a young and vibrant company where great people do great work. We offer a creative, dedicated, committed, passionate, and above all, fun environment where you can work, travel, meet world-renowned researchers and grow your career and experience.
\n\nTo apply, please email a copy of your CV and covering letter to hogan@intechopen.com stating your salary expectations.
\n\nNote: This full-time position will have an immediate start. In your cover letter, please indicate when you might be available for a block of two hours. As part of the interview process, all candidates that make it to the second phase will participate in a writing exercise.
\n\n*IntechOpen is an Equal Opportunities Employer consistent with its obligations under the law and does not discriminate against any employee or applicant on the basis of disability, gender, age, colour, national origin, race, religion, sexual orientation, war veteran status, or any classification protected by state, or local law.
\n'}]},successStories:{items:[]},authorsAndEditors:{filterParams:{sort:"featured,name"},profiles:[{id:"6700",title:"Dr.",name:"Abbass A.",middleName:null,surname:"Hashim",slug:"abbass-a.-hashim",fullName:"Abbass A. Hashim",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/6700/images/1864_n.jpg",biography:"Currently I am carrying out research in several areas of interest, mainly covering work on chemical and bio-sensors, semiconductor thin film device fabrication and characterisation.\nAt the moment I have very strong interest in radiation environmental pollution and bacteriology treatment. The teams of researchers are working very hard to bring novel results in this field. I am also a member of the team in charge for the supervision of Ph.D. students in the fields of development of silicon based planar waveguide sensor devices, study of inelastic electron tunnelling in planar tunnelling nanostructures for sensing applications and development of organotellurium(IV) compounds for semiconductor applications. I am a specialist in data analysis techniques and nanosurface structure. I have served as the editor for many books, been a member of the editorial board in science journals, have published many papers and hold many patents.",institutionString:null,institution:{name:"Sheffield Hallam University",country:{name:"United Kingdom"}}},{id:"54525",title:"Prof.",name:"Abdul Latif",middleName:null,surname:"Ahmad",slug:"abdul-latif-ahmad",fullName:"Abdul Latif Ahmad",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"20567",title:"Prof.",name:"Ado",middleName:null,surname:"Jorio",slug:"ado-jorio",fullName:"Ado Jorio",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universidade Federal de Minas Gerais",country:{name:"Brazil"}}},{id:"47940",title:"Dr.",name:"Alberto",middleName:null,surname:"Mantovani",slug:"alberto-mantovani",fullName:"Alberto Mantovani",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"12392",title:"Mr.",name:"Alex",middleName:null,surname:"Lazinica",slug:"alex-lazinica",fullName:"Alex Lazinica",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/12392/images/7282_n.png",biography:"Alex Lazinica is the founder and CEO of IntechOpen. After obtaining a Master's degree in Mechanical Engineering, he continued his PhD studies in Robotics at the Vienna University of Technology. Here he worked as a robotic researcher with the university's Intelligent Manufacturing Systems Group as well as a guest researcher at various European universities, including the Swiss Federal Institute of Technology Lausanne (EPFL). During this time he published more than 20 scientific papers, gave presentations, served as a reviewer for major robotic journals and conferences and most importantly he co-founded and built the International Journal of Advanced Robotic Systems- world's first Open Access journal in the field of robotics. Starting this journal was a pivotal point in his career, since it was a pathway to founding IntechOpen - Open Access publisher focused on addressing academic researchers needs. Alex is a personification of IntechOpen key values being trusted, open and entrepreneurial. Today his focus is on defining the growth and development strategy for the company.",institutionString:null,institution:{name:"TU Wien",country:{name:"Austria"}}},{id:"19816",title:"Prof.",name:"Alexander",middleName:null,surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/19816/images/1607_n.jpg",biography:"Alexander I. Kokorin: born: 1947, Moscow; DSc., PhD; Principal Research Fellow (Research Professor) of Department of Kinetics and Catalysis, N. Semenov Institute of Chemical Physics, Russian Academy of Sciences, Moscow.\r\nArea of research interests: physical chemistry of complex-organized molecular and nanosized systems, including polymer-metal complexes; the surface of doped oxide semiconductors. He is an expert in structural, absorptive, catalytic and photocatalytic properties, in structural organization and dynamic features of ionic liquids, in magnetic interactions between paramagnetic centers. The author or co-author of 3 books, over 200 articles and reviews in scientific journals and books. He is an actual member of the International EPR/ESR Society, European Society on Quantum Solar Energy Conversion, Moscow House of Scientists, of the Board of Moscow Physical Society.",institutionString:null,institution:{name:"Semenov Institute of Chemical Physics",country:{name:"Russia"}}},{id:"62389",title:"PhD.",name:"Ali Demir",middleName:null,surname:"Sezer",slug:"ali-demir-sezer",fullName:"Ali Demir Sezer",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/62389/images/3413_n.jpg",biography:"Dr. Ali Demir Sezer has a Ph.D. from Pharmaceutical Biotechnology at the Faculty of Pharmacy, University of Marmara (Turkey). He is the member of many Pharmaceutical Associations and acts as a reviewer of scientific journals and European projects under different research areas such as: drug delivery systems, nanotechnology and pharmaceutical biotechnology. Dr. Sezer is the author of many scientific publications in peer-reviewed journals and poster communications. Focus of his research activity is drug delivery, physico-chemical characterization and biological evaluation of biopolymers micro and nanoparticles as modified drug delivery system, and colloidal drug carriers (liposomes, nanoparticles etc.).",institutionString:null,institution:{name:"Marmara University",country:{name:"Turkey"}}},{id:"61051",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"100762",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"St David's Medical Center",country:{name:"United States of America"}}},{id:"107416",title:"Dr.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Texas Cardiac Arrhythmia",country:{name:"United States of America"}}},{id:"64434",title:"Dr.",name:"Angkoon",middleName:null,surname:"Phinyomark",slug:"angkoon-phinyomark",fullName:"Angkoon Phinyomark",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/64434/images/2619_n.jpg",biography:"My name is Angkoon Phinyomark. I received a B.Eng. degree in Computer Engineering with First Class Honors in 2008 from Prince of Songkla University, Songkhla, Thailand, where I received a Ph.D. degree in Electrical Engineering. My research interests are primarily in the area of biomedical signal processing and classification notably EMG (electromyography signal), EOG (electrooculography signal), and EEG (electroencephalography signal), image analysis notably breast cancer analysis and optical coherence tomography, and rehabilitation engineering. I became a student member of IEEE in 2008. During October 2011-March 2012, I had worked at School of Computer Science and Electronic Engineering, University of Essex, Colchester, Essex, United Kingdom. In addition, during a B.Eng. I had been a visiting research student at Faculty of Computer Science, University of Murcia, Murcia, Spain for three months.\n\nI have published over 40 papers during 5 years in refereed journals, books, and conference proceedings in the areas of electro-physiological signals processing and classification, notably EMG and EOG signals, fractal analysis, wavelet analysis, texture analysis, feature extraction and machine learning algorithms, and assistive and rehabilitative devices. I have several computer programming language certificates, i.e. Sun Certified Programmer for the Java 2 Platform 1.4 (SCJP), Microsoft Certified Professional Developer, Web Developer (MCPD), Microsoft Certified Technology Specialist, .NET Framework 2.0 Web (MCTS). I am a Reviewer for several refereed journals and international conferences, such as IEEE Transactions on Biomedical Engineering, IEEE Transactions on Industrial Electronics, Optic Letters, Measurement Science Review, and also a member of the International Advisory Committee for 2012 IEEE Business Engineering and Industrial Applications and 2012 IEEE Symposium on Business, Engineering and Industrial Applications.",institutionString:null,institution:{name:"Joseph Fourier University",country:{name:"France"}}},{id:"55578",title:"Dr.",name:"Antonio",middleName:null,surname:"Jurado-Navas",slug:"antonio-jurado-navas",fullName:"Antonio Jurado-Navas",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/55578/images/4574_n.png",biography:"Antonio Jurado-Navas received the M.S. degree (2002) and the Ph.D. degree (2009) in Telecommunication Engineering, both from the University of Málaga (Spain). He first worked as a consultant at Vodafone-Spain. From 2004 to 2011, he was a Research Assistant with the Communications Engineering Department at the University of Málaga. In 2011, he became an Assistant Professor in the same department. From 2012 to 2015, he was with Ericsson Spain, where he was working on geo-location\ntools for third generation mobile networks. Since 2015, he is a Marie-Curie fellow at the Denmark Technical University. His current research interests include the areas of mobile communication systems and channel modeling in addition to atmospheric optical communications, adaptive optics and statistics",institutionString:null,institution:{name:"University of Malaga",country:{name:"Spain"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:5766},{group:"region",caption:"Middle and South America",value:2,count:5228},{group:"region",caption:"Africa",value:3,count:1717},{group:"region",caption:"Asia",value:4,count:10370},{group:"region",caption:"Australia and Oceania",value:5,count:897},{group:"region",caption:"Europe",value:6,count:15791}],offset:12,limit:12,total:118192},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{topicId:"178"},books:[],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:16},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:4},{group:"topic",caption:"Business, Management and Economics",value:7,count:2},{group:"topic",caption:"Chemistry",value:8,count:8},{group:"topic",caption:"Computer and Information Science",value:9,count:6},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:7},{group:"topic",caption:"Engineering",value:11,count:19},{group:"topic",caption:"Environmental Sciences",value:12,count:2},{group:"topic",caption:"Immunology and Microbiology",value:13,count:3},{group:"topic",caption:"Materials Science",value:14,count:5},{group:"topic",caption:"Mathematics",value:15,count:1},{group:"topic",caption:"Medicine",value:16,count:24},{group:"topic",caption:"Neuroscience",value:18,count:2},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:3},{group:"topic",caption:"Physics",value:20,count:3},{group:"topic",caption:"Psychology",value:21,count:4},{group:"topic",caption:"Robotics",value:22,count:1},{group:"topic",caption:"Social Sciences",value:23,count:3},{group:"topic",caption:"Technology",value:24,count:1},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:1}],offset:12,limit:12,total:0},popularBooks:{featuredBooks:[{type:"book",id:"9385",title:"Renewable Energy",subtitle:"Technologies and Applications",isOpenForSubmission:!1,hash:"a6b446d19166f17f313008e6c056f3d8",slug:"renewable-energy-technologies-and-applications",bookSignature:"Tolga Taner, Archana Tiwari and Taha Selim Ustun",coverURL:"https://cdn.intechopen.com/books/images_new/9385.jpg",editors:[{id:"197240",title:"Associate Prof.",name:"Tolga",middleName:null,surname:"Taner",slug:"tolga-taner",fullName:"Tolga Taner"}],equalEditorOne:{id:"186791",title:"Dr.",name:"Archana",middleName:null,surname:"Tiwari",slug:"archana-tiwari",fullName:"Archana Tiwari",profilePictureURL:"https://mts.intechopen.com/storage/users/186791/images/system/186791.jpg",biography:"Dr. Archana Tiwari is Associate Professor at Amity University, India. Her research interests include renewable sources of energy from microalgae and further utilizing the residual biomass for the generation of value-added products, bioremediation through microalgae and microbial consortium, antioxidative enzymes and stress, and nutraceuticals from microalgae. She has been working on algal biotechnology for the last two decades. She has published her research in many international journals and has authored many books and chapters with renowned publishing houses. She has also delivered talks as an invited speaker at many national and international conferences. Dr. Tiwari is the recipient of several awards including Researcher of the Year and Distinguished Scientist.",institutionString:"Amity University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Amity University",institutionURL:null,country:{name:"India"}}},equalEditorTwo:{id:"197609",title:"Prof.",name:"Taha Selim",middleName:null,surname:"Ustun",slug:"taha-selim-ustun",fullName:"Taha Selim Ustun",profilePictureURL:"https://mts.intechopen.com/storage/users/197609/images/system/197609.jpeg",biography:"Dr. Taha Selim Ustun received a Ph.D. in Electrical Engineering from Victoria University, Melbourne, Australia. He is a researcher with the Fukushima Renewable Energy Institute, AIST (FREA), where he leads the Smart Grid Cybersecurity Laboratory. Prior to that, he was a faculty member with the School of Electrical and Computer Engineering, Carnegie Mellon University, Pittsburgh, PA, USA. His current research interests include power systems protection, communication in power networks, distributed generation, microgrids, electric vehicle integration, and cybersecurity in smart grids. He serves on the editorial boards of IEEE Access, IEEE Transactions on Industrial Informatics, Energies, Electronics, Electricity, World Electric Vehicle and Information journals. Dr. Ustun is a member of the IEEE 2004 and 2800, IEC Renewable Energy Management WG 8, and IEC TC 57 WG17. He has been invited to run specialist courses in Africa, India, and China. He has delivered talks for the Qatar Foundation, the World Energy Council, the Waterloo Global Science Initiative, and the European Union Energy Initiative (EUEI). His research has attracted funding from prestigious programs in Japan, Australia, the European Union, and North America.",institutionString:"Fukushima Renewable Energy Institute, AIST (FREA)",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"National Institute of Advanced Industrial Science and Technology",institutionURL:null,country:{name:"Japan"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9644",title:"Glaciers and the Polar Environment",subtitle:null,isOpenForSubmission:!1,hash:"e8cfdc161794e3753ced54e6ff30873b",slug:"glaciers-and-the-polar-environment",bookSignature:"Masaki Kanao, Danilo Godone and Niccolò Dematteis",coverURL:"https://cdn.intechopen.com/books/images_new/9644.jpg",editors:[{id:"51959",title:"Dr.",name:"Masaki",middleName:null,surname:"Kanao",slug:"masaki-kanao",fullName:"Masaki Kanao"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8985",title:"Natural Resources Management and Biological Sciences",subtitle:null,isOpenForSubmission:!1,hash:"5c2e219a6c021a40b5a20c041dea88c4",slug:"natural-resources-management-and-biological-sciences",bookSignature:"Edward R. Rhodes and Humood Naser",coverURL:"https://cdn.intechopen.com/books/images_new/8985.jpg",editors:[{id:"280886",title:"Prof.",name:"Edward R",middleName:null,surname:"Rhodes",slug:"edward-r-rhodes",fullName:"Edward R Rhodes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9671",title:"Macrophages",subtitle:null,isOpenForSubmission:!1,hash:"03b00fdc5f24b71d1ecdfd75076bfde6",slug:"macrophages",bookSignature:"Hridayesh Prakash",coverURL:"https://cdn.intechopen.com/books/images_new/9671.jpg",editors:[{id:"287184",title:"Dr.",name:"Hridayesh",middleName:null,surname:"Prakash",slug:"hridayesh-prakash",fullName:"Hridayesh Prakash"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9313",title:"Clay Science and Technology",subtitle:null,isOpenForSubmission:!1,hash:"6fa7e70396ff10620e032bb6cfa6fb72",slug:"clay-science-and-technology",bookSignature:"Gustavo Morari Do Nascimento",coverURL:"https://cdn.intechopen.com/books/images_new/9313.jpg",editors:[{id:"7153",title:"Prof.",name:"Gustavo",middleName:null,surname:"Morari Do Nascimento",slug:"gustavo-morari-do-nascimento",fullName:"Gustavo Morari Do Nascimento"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9888",title:"Nuclear Power Plants",subtitle:"The Processes from the Cradle to the Grave",isOpenForSubmission:!1,hash:"c2c8773e586f62155ab8221ebb72a849",slug:"nuclear-power-plants-the-processes-from-the-cradle-to-the-grave",bookSignature:"Nasser Awwad",coverURL:"https://cdn.intechopen.com/books/images_new/9888.jpg",editors:[{id:"145209",title:"Prof.",name:"Nasser",middleName:"S",surname:"Awwad",slug:"nasser-awwad",fullName:"Nasser Awwad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9027",title:"Human Blood Group Systems and Haemoglobinopathies",subtitle:null,isOpenForSubmission:!1,hash:"d00d8e40b11cfb2547d1122866531c7e",slug:"human-blood-group-systems-and-haemoglobinopathies",bookSignature:"Osaro Erhabor and Anjana Munshi",coverURL:"https://cdn.intechopen.com/books/images_new/9027.jpg",editors:[{id:"35140",title:null,name:"Osaro",middleName:null,surname:"Erhabor",slug:"osaro-erhabor",fullName:"Osaro Erhabor"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7841",title:"New Insights Into Metabolic Syndrome",subtitle:null,isOpenForSubmission:!1,hash:"ef5accfac9772b9e2c9eff884f085510",slug:"new-insights-into-metabolic-syndrome",bookSignature:"Akikazu Takada",coverURL:"https://cdn.intechopen.com/books/images_new/7841.jpg",editors:[{id:"248459",title:"Dr.",name:"Akikazu",middleName:null,surname:"Takada",slug:"akikazu-takada",fullName:"Akikazu Takada"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8558",title:"Aerodynamics",subtitle:null,isOpenForSubmission:!1,hash:"db7263fc198dfb539073ba0260a7f1aa",slug:"aerodynamics",bookSignature:"Mofid Gorji-Bandpy and Aly-Mousaad Aly",coverURL:"https://cdn.intechopen.com/books/images_new/8558.jpg",editors:[{id:"35542",title:"Prof.",name:"Mofid",middleName:null,surname:"Gorji-Bandpy",slug:"mofid-gorji-bandpy",fullName:"Mofid Gorji-Bandpy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7847",title:"Medical Toxicology",subtitle:null,isOpenForSubmission:!1,hash:"db9b65bea093de17a0855a1b27046247",slug:"medical-toxicology",bookSignature:"Pınar Erkekoglu and Tomohisa Ogawa",coverURL:"https://cdn.intechopen.com/books/images_new/7847.jpg",editors:[{id:"109978",title:"Prof.",name:"Pınar",middleName:null,surname:"Erkekoglu",slug:"pinar-erkekoglu",fullName:"Pınar Erkekoglu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10432",title:"Casting Processes and Modelling of Metallic Materials",subtitle:null,isOpenForSubmission:!1,hash:"2c5c9df938666bf5d1797727db203a6d",slug:"casting-processes-and-modelling-of-metallic-materials",bookSignature:"Zakaria Abdallah and Nada Aldoumani",coverURL:"https://cdn.intechopen.com/books/images_new/10432.jpg",editors:[{id:"201670",title:"Dr.",name:"Zak",middleName:null,surname:"Abdallah",slug:"zak-abdallah",fullName:"Zak Abdallah"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:5240},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9644",title:"Glaciers and the Polar Environment",subtitle:null,isOpenForSubmission:!1,hash:"e8cfdc161794e3753ced54e6ff30873b",slug:"glaciers-and-the-polar-environment",bookSignature:"Masaki Kanao, Danilo Godone and Niccolò Dematteis",coverURL:"https://cdn.intechopen.com/books/images_new/9644.jpg",editors:[{id:"51959",title:"Dr.",name:"Masaki",middleName:null,surname:"Kanao",slug:"masaki-kanao",fullName:"Masaki Kanao"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9385",title:"Renewable Energy",subtitle:"Technologies and Applications",isOpenForSubmission:!1,hash:"a6b446d19166f17f313008e6c056f3d8",slug:"renewable-energy-technologies-and-applications",bookSignature:"Tolga Taner, Archana Tiwari and Taha Selim Ustun",coverURL:"https://cdn.intechopen.com/books/images_new/9385.jpg",editors:[{id:"197240",title:"Associate Prof.",name:"Tolga",middleName:null,surname:"Taner",slug:"tolga-taner",fullName:"Tolga Taner"}],equalEditorOne:{id:"186791",title:"Dr.",name:"Archana",middleName:null,surname:"Tiwari",slug:"archana-tiwari",fullName:"Archana Tiwari",profilePictureURL:"https://mts.intechopen.com/storage/users/186791/images/system/186791.jpg",biography:"Dr. Archana Tiwari is Associate Professor at Amity University, India. Her research interests include renewable sources of energy from microalgae and further utilizing the residual biomass for the generation of value-added products, bioremediation through microalgae and microbial consortium, antioxidative enzymes and stress, and nutraceuticals from microalgae. She has been working on algal biotechnology for the last two decades. She has published her research in many international journals and has authored many books and chapters with renowned publishing houses. She has also delivered talks as an invited speaker at many national and international conferences. Dr. Tiwari is the recipient of several awards including Researcher of the Year and Distinguished Scientist.",institutionString:"Amity University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Amity University",institutionURL:null,country:{name:"India"}}},equalEditorTwo:{id:"197609",title:"Prof.",name:"Taha Selim",middleName:null,surname:"Ustun",slug:"taha-selim-ustun",fullName:"Taha Selim Ustun",profilePictureURL:"https://mts.intechopen.com/storage/users/197609/images/system/197609.jpeg",biography:"Dr. Taha Selim Ustun received a Ph.D. in Electrical Engineering from Victoria University, Melbourne, Australia. He is a researcher with the Fukushima Renewable Energy Institute, AIST (FREA), where he leads the Smart Grid Cybersecurity Laboratory. Prior to that, he was a faculty member with the School of Electrical and Computer Engineering, Carnegie Mellon University, Pittsburgh, PA, USA. His current research interests include power systems protection, communication in power networks, distributed generation, microgrids, electric vehicle integration, and cybersecurity in smart grids. He serves on the editorial boards of IEEE Access, IEEE Transactions on Industrial Informatics, Energies, Electronics, Electricity, World Electric Vehicle and Information journals. Dr. Ustun is a member of the IEEE 2004 and 2800, IEC Renewable Energy Management WG 8, and IEC TC 57 WG17. He has been invited to run specialist courses in Africa, India, and China. He has delivered talks for the Qatar Foundation, the World Energy Council, the Waterloo Global Science Initiative, and the European Union Energy Initiative (EUEI). His research has attracted funding from prestigious programs in Japan, Australia, the European Union, and North America.",institutionString:"Fukushima Renewable Energy Institute, AIST (FREA)",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"National Institute of Advanced Industrial Science and Technology",institutionURL:null,country:{name:"Japan"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8985",title:"Natural Resources Management and Biological Sciences",subtitle:null,isOpenForSubmission:!1,hash:"5c2e219a6c021a40b5a20c041dea88c4",slug:"natural-resources-management-and-biological-sciences",bookSignature:"Edward R. Rhodes and Humood Naser",coverURL:"https://cdn.intechopen.com/books/images_new/8985.jpg",editors:[{id:"280886",title:"Prof.",name:"Edward R",middleName:null,surname:"Rhodes",slug:"edward-r-rhodes",fullName:"Edward R Rhodes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9671",title:"Macrophages",subtitle:null,isOpenForSubmission:!1,hash:"03b00fdc5f24b71d1ecdfd75076bfde6",slug:"macrophages",bookSignature:"Hridayesh Prakash",coverURL:"https://cdn.intechopen.com/books/images_new/9671.jpg",editors:[{id:"287184",title:"Dr.",name:"Hridayesh",middleName:null,surname:"Prakash",slug:"hridayesh-prakash",fullName:"Hridayesh Prakash"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9313",title:"Clay Science and Technology",subtitle:null,isOpenForSubmission:!1,hash:"6fa7e70396ff10620e032bb6cfa6fb72",slug:"clay-science-and-technology",bookSignature:"Gustavo Morari Do Nascimento",coverURL:"https://cdn.intechopen.com/books/images_new/9313.jpg",editors:[{id:"7153",title:"Prof.",name:"Gustavo",middleName:null,surname:"Morari Do Nascimento",slug:"gustavo-morari-do-nascimento",fullName:"Gustavo Morari Do Nascimento"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9888",title:"Nuclear Power Plants",subtitle:"The Processes from the Cradle to the Grave",isOpenForSubmission:!1,hash:"c2c8773e586f62155ab8221ebb72a849",slug:"nuclear-power-plants-the-processes-from-the-cradle-to-the-grave",bookSignature:"Nasser Awwad",coverURL:"https://cdn.intechopen.com/books/images_new/9888.jpg",editors:[{id:"145209",title:"Prof.",name:"Nasser",middleName:"S",surname:"Awwad",slug:"nasser-awwad",fullName:"Nasser Awwad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9027",title:"Human Blood Group Systems and Haemoglobinopathies",subtitle:null,isOpenForSubmission:!1,hash:"d00d8e40b11cfb2547d1122866531c7e",slug:"human-blood-group-systems-and-haemoglobinopathies",bookSignature:"Osaro Erhabor and Anjana Munshi",coverURL:"https://cdn.intechopen.com/books/images_new/9027.jpg",editors:[{id:"35140",title:null,name:"Osaro",middleName:null,surname:"Erhabor",slug:"osaro-erhabor",fullName:"Osaro Erhabor"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10432",title:"Casting Processes and Modelling of Metallic Materials",subtitle:null,isOpenForSubmission:!1,hash:"2c5c9df938666bf5d1797727db203a6d",slug:"casting-processes-and-modelling-of-metallic-materials",bookSignature:"Zakaria Abdallah and Nada Aldoumani",coverURL:"https://cdn.intechopen.com/books/images_new/10432.jpg",editors:[{id:"201670",title:"Dr.",name:"Zak",middleName:null,surname:"Abdallah",slug:"zak-abdallah",fullName:"Zak Abdallah"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7841",title:"New Insights Into Metabolic Syndrome",subtitle:null,isOpenForSubmission:!1,hash:"ef5accfac9772b9e2c9eff884f085510",slug:"new-insights-into-metabolic-syndrome",bookSignature:"Akikazu Takada",coverURL:"https://cdn.intechopen.com/books/images_new/7841.jpg",editors:[{id:"248459",title:"Dr.",name:"Akikazu",middleName:null,surname:"Takada",slug:"akikazu-takada",fullName:"Akikazu Takada"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"9243",title:"Coastal Environments",subtitle:null,isOpenForSubmission:!1,hash:"8e05e5f631e935eef366980f2e28295d",slug:"coastal-environments",bookSignature:"Yuanzhi Zhang and X. San Liang",coverURL:"https://cdn.intechopen.com/books/images_new/9243.jpg",editedByType:"Edited by",editors:[{id:"77597",title:"Prof.",name:"Yuanzhi",middleName:null,surname:"Zhang",slug:"yuanzhi-zhang",fullName:"Yuanzhi Zhang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10020",title:"Operations Management",subtitle:"Emerging Trend in the Digital Era",isOpenForSubmission:!1,hash:"526f0dbdc7e4d85b82ce8383ab894b4c",slug:"operations-management-emerging-trend-in-the-digital-era",bookSignature:"Antonella Petrillo, Fabio De Felice, Germano Lambert-Torres and Erik Bonaldi",coverURL:"https://cdn.intechopen.com/books/images_new/10020.jpg",editedByType:"Edited by",editors:[{id:"181603",title:"Dr.",name:"Antonella",middleName:null,surname:"Petrillo",slug:"antonella-petrillo",fullName:"Antonella Petrillo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9521",title:"Antimicrobial Resistance",subtitle:"A One Health Perspective",isOpenForSubmission:!1,hash:"30949e78832e1afba5606634b52056ab",slug:"antimicrobial-resistance-a-one-health-perspective",bookSignature:"Mihai Mareș, Swee Hua Erin Lim, Kok-Song Lai and Romeo-Teodor Cristina",coverURL:"https://cdn.intechopen.com/books/images_new/9521.jpg",editedByType:"Edited by",editors:[{id:"88785",title:"Prof.",name:"Mihai",middleName:null,surname:"Mares",slug:"mihai-mares",fullName:"Mihai Mares"}],equalEditorOne:{id:"190224",title:"Dr.",name:"Swee Hua Erin",middleName:null,surname:"Lim",slug:"swee-hua-erin-lim",fullName:"Swee Hua Erin Lim",profilePictureURL:"https://mts.intechopen.com/storage/users/190224/images/system/190224.png",biography:"Dr. Erin Lim is presently working as an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates and is affiliated as an Associate Professor to Perdana University-Royal College of Surgeons in Ireland, Selangor, Malaysia. She obtained her Ph.D. from Universiti Putra Malaysia in 2010 with a National Science Fellowship awarded from the Ministry of Science, Technology and Innovation Malaysia and has been actively involved in research ever since. Her main research interests include analysis of carriage and transmission of multidrug resistant bacteria in non-conventional settings, besides an interest in natural products for antimicrobial testing. She is heavily involved in the elucidation of mechanisms of reversal of resistance in bacteria in addition to investigating the immunological analyses of diseases, development of vaccination and treatment models in animals. She hopes her work will support the discovery of therapeutics in the clinical setting and assist in the combat against the burden of antibiotic resistance.",institutionString:"Abu Dhabi Women’s College",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Perdana University",institutionURL:null,country:{name:"Malaysia"}}},equalEditorTwo:{id:"221544",title:"Dr.",name:"Kok-Song",middleName:null,surname:"Lai",slug:"kok-song-lai",fullName:"Kok-Song Lai",profilePictureURL:"https://mts.intechopen.com/storage/users/221544/images/system/221544.jpeg",biography:"Dr. Lai Kok Song is an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates. He obtained his Ph.D. in Biological Sciences from Nara Institute of Science and Technology, Japan in 2012. Prior to his academic appointment, Dr. Lai worked as a Senior Scientist at the Ministry of Science, Technology and Innovation, Malaysia. His current research areas include antimicrobial resistance and plant-pathogen interaction. His particular interest lies in the study of the antimicrobial mechanism via membrane disruption of essential oils against multi-drug resistance bacteria through various biochemical, molecular and proteomic approaches. Ultimately, he hopes to uncover and determine novel biomarkers related to antibiotic resistance that can be developed into new therapeutic strategies.",institutionString:"Higher Colleges of Technology",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"8",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Higher Colleges of Technology",institutionURL:null,country:{name:"United Arab Emirates"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9560",title:"Creativity",subtitle:"A Force to Innovation",isOpenForSubmission:!1,hash:"58f740bc17807d5d88d647c525857b11",slug:"creativity-a-force-to-innovation",bookSignature:"Pooja Jain",coverURL:"https://cdn.intechopen.com/books/images_new/9560.jpg",editedByType:"Edited by",editors:[{id:"316765",title:"Dr.",name:"Pooja",middleName:null,surname:"Jain",slug:"pooja-jain",fullName:"Pooja Jain"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9669",title:"Recent Advances in Rice Research",subtitle:null,isOpenForSubmission:!1,hash:"12b06cc73e89af1e104399321cc16a75",slug:"recent-advances-in-rice-research",bookSignature:"Mahmood-ur- Rahman Ansari",coverURL:"https://cdn.intechopen.com/books/images_new/9669.jpg",editedByType:"Edited by",editors:[{id:"185476",title:"Dr.",name:"Mahmood-Ur-",middleName:null,surname:"Rahman Ansari",slug:"mahmood-ur-rahman-ansari",fullName:"Mahmood-Ur- Rahman Ansari"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10192",title:"Background and Management of Muscular Atrophy",subtitle:null,isOpenForSubmission:!1,hash:"eca24028d89912b5efea56e179dff089",slug:"background-and-management-of-muscular-atrophy",bookSignature:"Julianna Cseri",coverURL:"https://cdn.intechopen.com/books/images_new/10192.jpg",editedByType:"Edited by",editors:[{id:"135579",title:"Dr.",name:"Julianna",middleName:null,surname:"Cseri",slug:"julianna-cseri",fullName:"Julianna Cseri"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9550",title:"Entrepreneurship",subtitle:"Contemporary Issues",isOpenForSubmission:!1,hash:"9b4ac1ee5b743abf6f88495452b1e5e7",slug:"entrepreneurship-contemporary-issues",bookSignature:"Mladen Turuk",coverURL:"https://cdn.intechopen.com/books/images_new/9550.jpg",editedByType:"Edited by",editors:[{id:"319755",title:"Prof.",name:"Mladen",middleName:null,surname:"Turuk",slug:"mladen-turuk",fullName:"Mladen Turuk"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editedByType:"Edited by",editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9313",title:"Clay Science and Technology",subtitle:null,isOpenForSubmission:!1,hash:"6fa7e70396ff10620e032bb6cfa6fb72",slug:"clay-science-and-technology",bookSignature:"Gustavo Morari Do Nascimento",coverURL:"https://cdn.intechopen.com/books/images_new/9313.jpg",editedByType:"Edited by",editors:[{id:"7153",title:"Prof.",name:"Gustavo",middleName:null,surname:"Morari Do Nascimento",slug:"gustavo-morari-do-nascimento",fullName:"Gustavo Morari Do Nascimento"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9888",title:"Nuclear Power Plants",subtitle:"The Processes from the Cradle to the Grave",isOpenForSubmission:!1,hash:"c2c8773e586f62155ab8221ebb72a849",slug:"nuclear-power-plants-the-processes-from-the-cradle-to-the-grave",bookSignature:"Nasser Awwad",coverURL:"https://cdn.intechopen.com/books/images_new/9888.jpg",editedByType:"Edited by",editors:[{id:"145209",title:"Prof.",name:"Nasser",middleName:"S",surname:"Awwad",slug:"nasser-awwad",fullName:"Nasser Awwad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"54",title:"Human Genetics",slug:"human-genetics",parent:{title:"Biochemistry, Genetics and Molecular Biology",slug:"biochemistry-genetics-and-molecular-biology"},numberOfBooks:31,numberOfAuthorsAndEditors:1019,numberOfWosCitations:1067,numberOfCrossrefCitations:413,numberOfDimensionsCitations:1019,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicSlug:"human-genetics",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"8073",title:"Chromosomal Abnormalities",subtitle:null,isOpenForSubmission:!1,hash:"6a9d3c58434edf5e65f9849a6858edfe",slug:"chromosomal-abnormalities",bookSignature:"Tülay Aşkın Çelik and Subrata Dey",coverURL:"https://cdn.intechopen.com/books/images_new/8073.jpg",editedByType:"Edited by",editors:[{id:"74041",title:"Dr.",name:"Tulay",middleName:null,surname:"Askin Celik",slug:"tulay-askin-celik",fullName:"Tulay Askin Celik"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6920",title:"Cytogenetics",subtitle:"Past, Present and Further Perspectives",isOpenForSubmission:!1,hash:"d72001eed508dfa72d9a68e1de28bb4b",slug:"cytogenetics-past-present-and-further-perspectives",bookSignature:"Marcelo Larramendy and Sonia Soloneski",coverURL:"https://cdn.intechopen.com/books/images_new/6920.jpg",editedByType:"Edited by",editors:[{id:"14764",title:"Dr.",name:"Marcelo L.",middleName:null,surname:"Larramendy",slug:"marcelo-l.-larramendy",fullName:"Marcelo L. Larramendy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6719",title:"Genetic Diversity and Disease Susceptibility",subtitle:null,isOpenForSubmission:!1,hash:"0c9919347cc7cb1dcbc245ce8684eee7",slug:"genetic-diversity-and-disease-susceptibility",bookSignature:"Yamin Liu",coverURL:"https://cdn.intechopen.com/books/images_new/6719.jpg",editedByType:"Edited by",editors:[{id:"201887",title:"Ph.D.",name:"Yamin",middleName:null,surname:"Liu",slug:"yamin-liu",fullName:"Yamin Liu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7204",title:"Gene Expression and Regulation in Mammalian Cells",subtitle:"Transcription Toward the Establishment of Novel Therapeutics",isOpenForSubmission:!1,hash:"10030057b2e2dee7d800ff27658c3a69",slug:"gene-expression-and-regulation-in-mammalian-cells-transcription-toward-the-establishment-of-novel-therapeutics",bookSignature:"Fumiaki Uchiumi",coverURL:"https://cdn.intechopen.com/books/images_new/7204.jpg",editedByType:"Edited by",editors:[{id:"47235",title:"Dr.",name:"Fumiaki",middleName:null,surname:"Uchiumi",slug:"fumiaki-uchiumi",fullName:"Fumiaki Uchiumi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6435",title:"Gene Expression and Regulation in Mammalian Cells",subtitle:"Transcription From General Aspects",isOpenForSubmission:!1,hash:"8573c44c537def5c800a0f6d4ed844d6",slug:"gene-expression-and-regulation-in-mammalian-cells-transcription-from-general-aspects",bookSignature:"Fumiaki Uchiumi",coverURL:"https://cdn.intechopen.com/books/images_new/6435.jpg",editedByType:"Edited by",editors:[{id:"47235",title:"Dr.",name:"Fumiaki",middleName:null,surname:"Uchiumi",slug:"fumiaki-uchiumi",fullName:"Fumiaki Uchiumi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5784",title:"Antibody Engineering",subtitle:null,isOpenForSubmission:!1,hash:"2c8c3e133140fbc7f563918285e7c3c2",slug:"antibody-engineering",bookSignature:"Thomas Böldicke",coverURL:"https://cdn.intechopen.com/books/images_new/5784.jpg",editedByType:"Edited by",editors:[{id:"176804",title:"Dr.",name:"Thomas",middleName:null,surname:"Böldicke",slug:"thomas-boldicke",fullName:"Thomas Böldicke"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5986",title:"The Role of Matrix Metalloproteinase in Human Body Pathologies",subtitle:null,isOpenForSubmission:!1,hash:"ef3e8940d7f0b229028d6fb71b1e0927",slug:"the-role-of-matrix-metalloproteinase-in-human-body-pathologies",bookSignature:"Francesco Travascio",coverURL:"https://cdn.intechopen.com/books/images_new/5986.jpg",editedByType:"Edited by",editors:[{id:"172239",title:"Dr.",name:"Francesco",middleName:null,surname:"Travascio",slug:"francesco-travascio",fullName:"Francesco Travascio"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5817",title:"Embryo Cleavage",subtitle:null,isOpenForSubmission:!1,hash:"11de486fcf8fe42d4359c65e71a8f1da",slug:"embryo-cleavage",bookSignature:"Bin Wu",coverURL:"https://cdn.intechopen.com/books/images_new/5817.jpg",editedByType:"Edited by",editors:[{id:"108807",title:"Ph.D.",name:"Bin",middleName:null,surname:"Wu",slug:"bin-wu",fullName:"Bin Wu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"4588",title:"New Discoveries in Embryology",subtitle:null,isOpenForSubmission:!1,hash:"2d40aace9724b9c451a8d8168acd0169",slug:"new-discoveries-in-embryology",bookSignature:"Bin Wu",coverURL:"https://cdn.intechopen.com/books/images_new/4588.jpg",editedByType:"Edited by",editors:[{id:"108807",title:"Ph.D.",name:"Bin",middleName:null,surname:"Wu",slug:"bin-wu",fullName:"Bin Wu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"4594",title:"胚胎移植新进展",subtitle:"Advances in Embryo Transfer",isOpenForSubmission:!1,hash:"32b738c0d0cbce7a61a3ea63b5d43ed0",slug:"advances-in-embryo-transfer-translation-chinese",bookSignature:"Bin Wu",coverURL:"https://cdn.intechopen.com/books/images_new/4594.jpg",editedByType:"Edited by",editors:[{id:"108807",title:"Ph.D.",name:"Bin",middleName:null,surname:"Wu",slug:"bin-wu",fullName:"Bin Wu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1907",title:"Reviews on Selected Topics of Telomere Biology",subtitle:null,isOpenForSubmission:!1,hash:"5f4f25ba706645403bab2aa721a0809b",slug:"reviews-on-selected-topics-of-telomere-biology",bookSignature:"Bibo Li",coverURL:"https://cdn.intechopen.com/books/images_new/1907.jpg",editedByType:"Edited by",editors:[{id:"109879",title:"Dr.",name:"Bibo",middleName:null,surname:"Li",slug:"bibo-li",fullName:"Bibo Li"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2518",title:"Binding Protein",subtitle:null,isOpenForSubmission:!1,hash:"6e70c7a9b0007d8f78ae4f3effba9664",slug:"binding-protein",bookSignature:"Kotb Abdelmohsen",coverURL:"https://cdn.intechopen.com/books/images_new/2518.jpg",editedByType:"Edited by",editors:[{id:"144861",title:"Dr.",name:"Kotb",middleName:null,surname:"Abdelmohsen",slug:"kotb-abdelmohsen",fullName:"Kotb Abdelmohsen"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:31,mostCitedChapters:[{id:"38236",doi:"10.5772/50129",title:"Extrinsic and Intrinsic Apoptosis Signal Pathway Review",slug:"extrinsic-and-intrinsic-apoptosis-signal-pathway-review",totalDownloads:10544,totalCrossrefCites:33,totalDimensionsCites:61,book:{slug:"apoptosis-and-medicine",title:"Apoptosis and Medicine",fullTitle:"Apoptosis and Medicine"},signatures:"Zhao Hongmei",authors:[{id:"146795",title:"Dr.",name:"Zhao",middleName:null,surname:"Hongmei",slug:"zhao-hongmei",fullName:"Zhao Hongmei"}]},{id:"35489",doi:"10.5772/37107",title:"MM-GB(PB)SA Calculations of Protein-Ligand Binding Free Energies",slug:"mm-gb-pb-sa-calculations-of-protein-ligand-binding-free-energies",totalDownloads:8040,totalCrossrefCites:9,totalDimensionsCites:45,book:{slug:"molecular-dynamics-studies-of-synthetic-and-biological-macromolecules",title:"Molecular Dynamics",fullTitle:"Molecular Dynamics - Studies of Synthetic and Biological Macromolecules"},signatures:"Joseph M. Hayes and Georgios Archontis",authors:[{id:"102666",title:"Dr.",name:"Joseph",middleName:"M.",surname:"Hayes",slug:"joseph-hayes",fullName:"Joseph Hayes"},{id:"111282",title:"Prof.",name:"Georgios",middleName:null,surname:"Archontis",slug:"georgios-archontis",fullName:"Georgios Archontis"}]},{id:"38806",doi:"10.5772/48277",title:"Bacterial Two-Component Systems: Structures and Signaling Mechanisms",slug:"bacterial-two-component-systems-structures-and-signaling-mechanisms",totalDownloads:4694,totalCrossrefCites:14,totalDimensionsCites:28,book:{slug:"protein-phosphorylation-in-human-health",title:"Protein Phosphorylation in Human Health",fullTitle:"Protein Phosphorylation in Human Health"},signatures:"Shuishu Wang",authors:[{id:"141519",title:"Dr.",name:"Shuishu",middleName:null,surname:"Wang",slug:"shuishu-wang",fullName:"Shuishu Wang"}]}],mostDownloadedChaptersLast30Days:[{id:"62578",title:"DNA Polymorphisms: DNA-Based Molecular Markers and Their Application in Medicine",slug:"dna-polymorphisms-dna-based-molecular-markers-and-their-application-in-medicine",totalDownloads:3132,totalCrossrefCites:3,totalDimensionsCites:4,book:{slug:"genetic-diversity-and-disease-susceptibility",title:"Genetic Diversity and Disease Susceptibility",fullTitle:"Genetic Diversity and Disease Susceptibility"},signatures:"Salwa Teama",authors:[{id:"249329",title:"Dr.",name:"Salwa",middleName:null,surname:"Teama",slug:"salwa-teama",fullName:"Salwa Teama"}]},{id:"59173",title:"Separation of Monoclonal Antibodies by Analytical Size Exclusion Chromatography",slug:"separation-of-monoclonal-antibodies-by-analytical-size-exclusion-chromatography",totalDownloads:2846,totalCrossrefCites:0,totalDimensionsCites:2,book:{slug:"antibody-engineering",title:"Antibody Engineering",fullTitle:"Antibody Engineering"},signatures:"Atis Chakrabarti",authors:[{id:"199389",title:"Ph.D.",name:"Atis",middleName:null,surname:"Chakrabarti",slug:"atis-chakrabarti",fullName:"Atis Chakrabarti"}]},{id:"56481",title:"Detailed Protocols for the Selection of Antiviral Human Antibodies from Combinatorial Immune Phage Display Libraries",slug:"detailed-protocols-for-the-selection-of-antiviral-human-antibodies-from-combinatorial-immune-phage-d",totalDownloads:1369,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"antibody-engineering",title:"Antibody Engineering",fullTitle:"Antibody Engineering"},signatures:"Philipp Diebolder and Adalbert Krawczyk",authors:[{id:"198001",title:"Dr.",name:"Adalbert",middleName:null,surname:"Krawczyk",slug:"adalbert-krawczyk",fullName:"Adalbert Krawczyk"},{id:"198002",title:"Dr.",name:"Philipp",middleName:null,surname:"Diebolder",slug:"philipp-diebolder",fullName:"Philipp Diebolder"}]},{id:"38804",title:"The Prp4 Kinase: Its Substrates, Function and Regulation in Pre-mRNA Splicing",slug:"the-prp4-kinase-its-substrates-function-and-regulation-in-pre-mrna-splicing",totalDownloads:2303,totalCrossrefCites:2,totalDimensionsCites:7,book:{slug:"protein-phosphorylation-in-human-health",title:"Protein Phosphorylation in Human Health",fullTitle:"Protein Phosphorylation in Human Health"},signatures:"Martin Lützelberger and Norbert F. Käufer",authors:[{id:"141382",title:"Prof.",name:"Norbert",middleName:"F.",surname:"Käufer",slug:"norbert-kaufer",fullName:"Norbert Käufer"},{id:"144512",title:"Dr.",name:"Martin",middleName:null,surname:"Lützelberger",slug:"martin-lutzelberger",fullName:"Martin Lützelberger"}]},{id:"49200",title:"Human Embryology",slug:"human-embryology",totalDownloads:2688,totalCrossrefCites:2,totalDimensionsCites:3,book:{slug:"new-discoveries-in-embryology",title:"New Discoveries in Embryology",fullTitle:"New Discoveries in Embryology"},signatures:"Shigehito Yamada, Mark Hill and Tetsuya Takakuwa",authors:[{id:"49486",title:"Prof.",name:"Shigehito",middleName:null,surname:"Yamada",slug:"shigehito-yamada",fullName:"Shigehito Yamada"},{id:"90205",title:"Prof.",name:"Tetsuya",middleName:null,surname:"Takakuwa",slug:"tetsuya-takakuwa",fullName:"Tetsuya Takakuwa"},{id:"175453",title:"Dr.",name:"Mark",middleName:null,surname:"Hill",slug:"mark-hill",fullName:"Mark Hill"}]},{id:"58467",title:"Generation of Antibody Diversity",slug:"generation-of-antibody-diversity",totalDownloads:2024,totalCrossrefCites:1,totalDimensionsCites:1,book:{slug:"antibody-engineering",title:"Antibody Engineering",fullTitle:"Antibody Engineering"},signatures:"Oliver Backhaus",authors:[{id:"177685",title:"M.Sc.",name:"Oliver",middleName:null,surname:"Backhaus",slug:"oliver-backhaus",fullName:"Oliver Backhaus"}]},{id:"40892",title:"Control of Telomere Length in Drosophila",slug:"control-of-telomere-length-in-drosophila",totalDownloads:1455,totalCrossrefCites:3,totalDimensionsCites:5,book:{slug:"reviews-on-selected-topics-of-telomere-biology",title:"Reviews on Selected Topics of Telomere Biology",fullTitle:"Reviews on Selected Topics of Telomere Biology"},signatures:"Sergey Shpiz and Alla Kalmykova",authors:[{id:"115829",title:"Dr.",name:"Alla",middleName:null,surname:"Kalmykova",slug:"alla-kalmykova",fullName:"Alla Kalmykova"},{id:"117877",title:"Dr.",name:"Sergey",middleName:null,surname:"Shpiz",slug:"sergey-shpiz",fullName:"Sergey Shpiz"}]},{id:"39204",title:"Modulation of Gene Expression by RNA Binding Proteins: mRNA Stability and Translation",slug:"modulation-of-gene-expression-by-rna-binding-proteins-mrna-stability-and-translation",totalDownloads:4940,totalCrossrefCites:2,totalDimensionsCites:6,book:{slug:"binding-protein",title:"Binding Protein",fullTitle:"Binding Protein"},signatures:"Kotb Abdelmohsen",authors:[{id:"144861",title:"Dr.",name:"Kotb",middleName:null,surname:"Abdelmohsen",slug:"kotb-abdelmohsen",fullName:"Kotb Abdelmohsen"}]},{id:"19303",title:"Archaeal DNA Repair Nucleases",slug:"archaeal-dna-repair-nucleases",totalDownloads:2322,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"dna-repair-on-the-pathways-to-fixing-dna-damage-and-errors",title:"DNA Repair",fullTitle:"DNA Repair - On the Pathways to Fixing DNA Damage and Errors"},signatures:"Roxanne Lestini, Christophe Creze, Didier Flament, Hannu Myllykallio and Ghislaine Henneke",authors:[{id:"44844",title:"Dr.",name:"Hannu",middleName:null,surname:"Myllykallio",slug:"hannu-myllykallio",fullName:"Hannu Myllykallio"},{id:"51718",title:"Dr.",name:"Ghislaine",middleName:null,surname:"Henneke",slug:"ghislaine-henneke",fullName:"Ghislaine Henneke"},{id:"57263",title:"Dr.",name:"Rosane",middleName:null,surname:"Lestini",slug:"rosane-lestini",fullName:"Rosane Lestini"},{id:"57264",title:"Dr.",name:"Christophe",middleName:null,surname:"Creze",slug:"christophe-creze",fullName:"Christophe Creze"},{id:"57265",title:"Dr.",name:"Didier",middleName:null,surname:"Flament",slug:"didier-flament",fullName:"Didier Flament"}]},{id:"38242",title:"Cell Death and Cancer, Novel Therapeutic Strategies",slug:"cell-death-and-cancer-novel-therapeutic-strategies",totalDownloads:3117,totalCrossrefCites:3,totalDimensionsCites:4,book:{slug:"apoptosis-and-medicine",title:"Apoptosis and Medicine",fullTitle:"Apoptosis and Medicine"},signatures:"Silvina Grasso, M. Piedad Menéndez-Gutiérrez, Estefanía Carrasco-García, Leticia Mayor-López, Elena Tristante, Lourdes Rocamora-Reverte, Ángeles Gómez-Martínez, Pilar García-Morales, José A. Ferragut, Miguel Saceda and Isabel Martínez-Lacaci",authors:[{id:"145739",title:"Dr.",name:"Isabel",middleName:null,surname:"Martinez-Lacaci",slug:"isabel-martinez-lacaci",fullName:"Isabel Martinez-Lacaci"}]}],onlineFirstChaptersFilter:{topicSlug:"human-genetics",limit:3,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[{type:"book",id:"10176",title:"Microgrids and Local Energy Systems",subtitle:null,isOpenForSubmission:!0,hash:"c32b4a5351a88f263074b0d0ca813a9c",slug:null,bookSignature:"Prof. Nick Jenkins",coverURL:"https://cdn.intechopen.com/books/images_new/10176.jpg",editedByType:null,editors:[{id:"55219",title:"Prof.",name:"Nick",middleName:null,surname:"Jenkins",slug:"nick-jenkins",fullName:"Nick Jenkins"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:8,limit:8,total:1},route:{name:"profile.detail",path:"/profiles/311549/jetsada-posom",hash:"",query:{},params:{id:"311549",slug:"jetsada-posom"},fullPath:"/profiles/311549/jetsada-posom",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()